Incidence and mortality rates of Guillain-Barré syndrome in Serbia
Aleksandar Stojanov
Neurology Clinic, Clinical Center Nis, Nis, Serbia
Search for more papers by this authorIvana Berisavac
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for more papers by this authorIvo Bozovic
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Search for more papers by this authorMirjana Arsenijevic
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Search for more papers by this authorSonja Lukic-Rajic
Neurology Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia
Search for more papers by this authorMilutin Petrovic
Neurology Clinic, Clinical Center Kragujevac, Kragujevac, Serbia
Search for more papers by this authorOlivera Stojiljkovic-Tamas
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Search for more papers by this authorZita Jovin
Neurology Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia
Search for more papers by this authorGordana Djordjevic
Neurology Clinic, Clinical Center Nis, Nis, Serbia
Faculty of Medicine, University of Nis, Nis, Serbia
Search for more papers by this authorDejana Jovanovic
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for more papers by this authorMiroslav Stojanovic
Neurology Clinic, Clinical Center Kragujevac, Kragujevac, Serbia
Search for more papers by this authorVesna Martic
Neurology Clinic, Military Medical Academy, Belgrade, Serbia
Search for more papers by this authorIvana Basta
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for more papers by this authorCorresponding Author
Stojan Peric
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Correspondence
Stojan Peric, MD, PhD, Dr Subotic Street 6, 11000 Belgrade, Serbia.
Email: [email protected]
Search for more papers by this authorAleksandar Stojanov
Neurology Clinic, Clinical Center Nis, Nis, Serbia
Search for more papers by this authorIvana Berisavac
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for more papers by this authorIvo Bozovic
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Search for more papers by this authorMirjana Arsenijevic
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Search for more papers by this authorSonja Lukic-Rajic
Neurology Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia
Search for more papers by this authorMilutin Petrovic
Neurology Clinic, Clinical Center Kragujevac, Kragujevac, Serbia
Search for more papers by this authorOlivera Stojiljkovic-Tamas
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Search for more papers by this authorZita Jovin
Neurology Clinic, Clinical Center of Vojvodina, Novi Sad, Serbia
Search for more papers by this authorGordana Djordjevic
Neurology Clinic, Clinical Center Nis, Nis, Serbia
Faculty of Medicine, University of Nis, Nis, Serbia
Search for more papers by this authorDejana Jovanovic
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for more papers by this authorMiroslav Stojanovic
Neurology Clinic, Clinical Center Kragujevac, Kragujevac, Serbia
Search for more papers by this authorVesna Martic
Neurology Clinic, Military Medical Academy, Belgrade, Serbia
Search for more papers by this authorIvana Basta
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Search for more papers by this authorCorresponding Author
Stojan Peric
Neurology Clinic, Clinical Center of Serbia, Belgrade, Serbia
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
Correspondence
Stojan Peric, MD, PhD, Dr Subotic Street 6, 11000 Belgrade, Serbia.
Email: [email protected]
Search for more papers by this authorAbstract
Guillain-Barré syndrome (GBS) is an acute auto-immune polyradiculoneuropathy. A huge variety of GBS incidence and mortality rates has been noted across the world. The objective of the present multi-centric study was to assess the incidence and mortality rates of GBS during a 10-year period in Serbia. We collected data of adult GBS patients who were hospitalized from 2009 to 2018 in all five tertiary healthcare centers in Serbia. The incidence rates per 100 000 inhabitants with 95% confidence intervals (CI) were calculated and further corrected for the estimated number of patients hospitalized in secondary centers. Mortality rates were also assessed. GBS was considered severe if patients were not able to walk at least 10 m without assistance. Six hundred and forty GBS patients were registered in tertiary centers in a 10-year period. The proportion of severe cases was 75% at nadir, and 52% on discharge. GBS incidence rate in Serbia was 1.1 per 100 000 inhabitants, and estimated incidence if patients from secondary centers included 1.2 per 100 000. Peak incidence was observed during the sixth decade of life. During the acute phase, 5.6% of GBS patients died, while overall 9.7% of them died during 6-month period from disease onset. This study contributes to our knowledge about GBS epidemiology. Results will allow us to improve the diagnosis and treatment of GBS patients in Serbia.
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
- 1van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014; 10: 469-482.
- 2Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011; 36: 123-133.
- 3Inokuchi H, Yasunaga H, Nakahara Y, et al. Effect of rehabilitation on mortality of patients with Guillain-Barre syndrome: a propensity matched analysis using nationwide database. Eur J Phys Rehabil Med. 2014; 50: 439-446.
- 4 The Italian Guillain–Barré syndrome Study Group. The prognosis and main prognostic indicators of Guillain–Barré syndrome: a multicenter prospective study of 297 patients. Brain. 1996; 119: 2053-2061.
- 5Cheng Q, Wang DS, Jiang GX, et al. Prospective study of clinical epidemiology of Guillain–Barré syndrome in Harbin, China. J Neurol Sci. 2003; 215: 63-69.
- 6Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barré syndrome admitted to the intensive care unit. J Neurol Sci. 2008; 264: 121-128.
- 7Lawn ND, Wijdicks FM. Fatal Guillain-Barré syndrome. Neurology. 1999; 52: 635-638.
- 8Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018; 141(10): 2866-2877.
- 9Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016; 388(10045): 717-727.
- 10Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995; 118: 597-605.
- 11González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol. 2013; 13: 95.
- 12McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009; 32: 150-163.
- 13Grapperon AM, Berro M, Salort-Campana E, Verschueren A, Delmont E, Attarian S. Guillain-Barré syndrome subtypes: a clinical electrophysiological study of 100 patients. Rev Neurol (Paris). 2019; 175(1–2): 73-80.
- 14Huang WC, Lu CL, Chen SC. A 15-year nationwide epidemiological analysis of Guillain-Barré syndrome in Taiwan. Neuroepidemiology. 2015; 44: 249-254.
- 15Islam Z, Jacobs BC, van Belkum A, et al. Axonal variant of Guillain-Barré syndrome associated with campylobacter infection in Bangladesh. Neurology. 2010; 74: 581-587.
- 16Peric S, Milosevic V, Berisavac I, et al. Clinical and epidemiological features of Guillain-Barré syndrome in the Western Balkans. J Peripher Nerv Syst. 2014; 19(4): 317-321.
- 17Hadden RD, Cornblath DR, Hughes RA, et al.; Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial GroupElectrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol. 1998; 44(5): 780-788.
- 18Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978; 2: 750-753.
- 19Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008; 70(18): 1608-1613.
- 20Sipilä JOT, Soilu-Hänninen M, Ruuskanen JO, Rautava P, Kytö V. Epidemiology of Guillain-Barré syndrome in Finland 2004-2014. J Peripher Nerv Syst. 2017; 22(4): 440-445.
- 21Al-Hakem H, Sindrup SH, Andersen H, et al. Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. J Neurol. 2019; 266(2): 440-449.
- 22Chroni E, Papapetropoulos S, Gioldasis G, Ellul J, Diamadopoulos N, Papapetropoulos T. Guillain-Barré syndrome in Greece: seasonality and other clinico-epidemiological features. Eur J Neurol. 2004; 11(6): 383-388.
- 23Cuadrado JI, de Pedro-Cuesta J, Ara JR, et al. Public health surveillance and incidence of adulthood Guillain-Barré syndrome in Spain, 1998–1999: the view from a sentinel network of neurologists. Neurol Sci. 2004; 25: 57-65.
- 24Markoula S, Giannopoulos S, Sarmas I, Tzavidi S, Kyritsis AP, Lagos G. Guillain-Barré syndrome in Northwest Greece. Acta Neurol Scand. 2007; 115: 167-173.
- 25Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med. 2012; 366: 2294-2304.
- 26Hafsteinsdottir B, Olafsson E. Incidence and natural history of idiopathic chronic inflammatory demyelinating polyneuropathy: a population-based study in Iceland. Eur Neurol. 2016; 75(5–6): 263-268.
- 27Löscher WN, Oberreiter EM, Erdler M, et al. Multifocal motor neuropathy in Austria: a nationwide survey of clinical features and response to treatment. J Neurol. 2018; 265(12): 2834-2840.
- 28Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barre syndrome in the United Kingdom, 1992 to 2000. Arch Intern Med. 2006; 166: 1301-1304.
- 29Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita. 2016; 52(2): 205-212.
- 30Blum S, Reddel S, Spies J, McCombe P. Clinical features of patients with Guillain-Barré syndrome at seven hospitals on the East Coast of Australia. J Peripher Nerv Syst. 2013; 18: 316-320.
- 31Cheng Q, Wang DS, Jiang GX, et al. Distinct pattern of age-specific incidence of Guillain-Barré syndrome in Harbin, China. J Neurol. 2002; 249: 25-32.
- 32Chen Y, Ma F, Zhang J, Chu X, Xu Y. Population incidence of Guillain-Barré syndrome in parts of China: three large populations in Jiangsu province, 2008–2010. Eur J Neurol. 2014; 21: 124-129.
- 33Zhang B, Wu X, Shen D, et al. The clinical characteristics and short-term prognosis in elderly patients with Guillain–Barré syndrome. Medicine (Baltimore). 2017; 96(1): e5848.
- 34Shui IM, Rett MD, Weintraub E, et al. Guillain-Barré syndrome incidence in a large United States cohort (2000–2009). Neuroepidemiology. 2012; 39: 109-115.
- 35van der Maas NA, Kramer MA, Jacobs BC, et al. Guillain-Barré syndrome: background incidence rates in The Netherlands. J Peripher Nerv Syst. 2011; 16(3): 243-249.
- 36Webb AJ, Brain SA, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. Neurol Neurosurg Psychiatry. 2015; 86(11): 1196-1201.
- 37Cheng BC, Chang WN, Chang CS, et al. Guillain-Barré syndrome in southern Taiwan: clinical features, prognostic factors and therapeutic outcomes. Eur J Neurol. 2003; 10: 655-662.
- 38Liu S, Xiao Z, Lou M, et al. Guillain-Barré syndrome in southern China: retrospective analysis of hospitalized patients from 14 provinces in the area south of the Huaihe River. Neurol Neurosurg Psychiatry. 2018; 89(6): 618-626.
- 39Matsui N, Nodera H, Kuzume D, et al. Guillain-Barré syndrome in a local area in Japan, 2006-2015: an epidemiological and clinical study of 108 patients. Eur J Neurol. 2018; 25(5): 718-724.
- 40Kuwabara S, Yuki N. Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol. 2013; 12(12): 1180-1188.
- 41Chiò A, Cocito D, Leone M, et al. Guillain-Barré syndrome: a prospective, population-based incidence and outcome survey. Neurology. 2003; 60: 1146-1150.
- 42Uncini A, Kuwabara S. The electrodiagnosis of Guillain-Barré syndrome subtypes: where do we stand? Clin Neurophysiol. 2018; 129(12): 2586-2593.
- 43van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013; 80: 1650-1654.
- 44Hafsteinsdóttir B, Ólafsson E, Jakobsson F. Incidence and outcome of Guillain-Barré syndrome in Iceland: a population-based study. Acta Neurol Scand. 2018; 138(5): 454-458.
- 45Wong AH, Umapathi T, Shahrizaila N, Chan YC, Kokubun N, Fong MK, et al. The value of comparing mortality of Guillain–Barré syndrome across different regions. J Neurol Sci 2014; 15; 344(1–2): 60–62.
- 46Bhagat SK, Sidhant S, Bhatta M, Ghimire A, Shah B. Clinical profile, functional outcome, and mortality of Guillain-Barre syndrome: a five-year tertiary care experience from Nepal. Neurol Res Int. 2019; 2019: 3867946.
- 47H Siddiqui S, H Siddiqui T, U Babar M, Khoja A, Khan S. Outcomes of patients with Guillain Barre syndrome - experience from a tertiary care hospital of a developing Asian country and review of regional literature. J Clin Neurosci. 2019; 62: 195-198.
- 48van den Berg B, Storm EF, Garssen MJP, Blomkwist-Markens PH, Jacobs BC. Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation. J Neurol Neurosurg Psychiatry. 2018; 89(9): 949-954.
Citing Literature
